Back

CRISPR/Cas9 editing of CaMKII as a strategy for cardioprotection against ischemia/reperfusion injury.

28 August 2022 (08:45 - 09:00)
Organised by:
Congress Presentation Part of: Basic and Translational Late-Breaking Science 1 Ischaemia, Infarction, Cardioprotection ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Simon Lebek

University Hospital Regensburg, Regensburg (Germany)

3 More presentations in this session

Presentation thumbnail
Intravascular administration of soluble Sars-CoV-2 Spike protein triggers non-infective heart and lung inflammation and vascular pericytes rarefaction in healthy mice.
Doctor E. Avolio (Bristol, GB)
Slides Video
Presentation thumbnail
Is empagliflozin still cardioprotective in SGLT2 KO mice?
Miss S. Chen (Amsterdam, NL)
Slides Video
Presentation thumbnail
Plasma of COVID-19 positive patients promote oxidative stress and proinflammatory responses in endothelial cells: Potential role of the pro-inflammatory cytokines/SGLT2 pathway.
Doctor A. Mroueh (Strasbourg, FR)
Slides Video

Access the full session

Session thumbnail
Basic and Translational Late-Breaking Science 1
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 08:45 CET
You may be interested in
thumbnail
Congress Presentation
Gene/base editing as therapy for common cardiovascular disorders
thumbnail
Congress Session
Gene editing and gene therapies to cure cardiovascular diseases
thumbnail
Congress Presentation
Gene editing to correct disease-causing mutations in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources